Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04947735 · ClinicalTrials.gov registry record · NA
CYPRESS Efficacy and Safety Study Extension
A NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
- Active
- Registry status
- NA
- Development phase
- 200
- Enrollment target
- 12
- Study locations
NCT04947735: Active NA study of Myopia and Juvenile Myopia, sponsored by SightGlass Vision.
NCT04947735 is a NA study of Myopia and Juvenile Myopia that is active but no longer recruiting, run by SightGlass Vision. The registered enrollment target is 200 participants, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (25% lower). The trial reports 12 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04947735, a NA study of Myopia and Juvenile Myopia, is active but no longer recruiting, sponsored by SightGlass Vision.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 200 participants
- Enrollment target
- 12
- Study locations
Study Summary
This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.
Primary Outcome
Test vs. control axial length change from baseline
Conditions Studied
Interventions
- DEVICE Novel spectacle lens design
- DEVICE Spectacle lenses
Study Locations (12)
New York
- SUNY School of Optometry - New York
- Sacco Eye Group - Vestal
California
- Golden Optometric Group - Whittier
Florida
- Omega Vision Center, PA - Longwood
Kansas
- Kannarr Eye Care - Pittsburg
Louisiana
- Haik Humble - West Monroe
Missouri
- Advanced Eyecare PC - Raytown
South Dakota
- Dunes Eye Consultants - Dakota Dunes
Tennessee
- Total Eye Care - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 200 participants |
| Start Date | 2021-07-19 |
| Est. Completion | 2026-03-31 |
| Phase | NA |
What the registry record for NCT04947735 still lists
NCT04947735 is an interventional study that assigns participants to a tested intervention. The registered 200 participants enrollment target is mid-sized for trials with a published cap, below the 266-participant average among 90 other Myopia trials with a reported enrollment target (25% lower).
The record links to 2 conditions, with Myopia appearing as the primary indexed condition, and to 2 interventions - of which Novel spectacle lens design is the first listed.
NCT04947735 lists 12 locations in 11 states (New York, California, Florida).
Frequently Asked Questions
What is clinical trial NCT04947735 about?
NCT04947735 is a clinical study titled "CYPRESS Efficacy and Safety Study Extension". This is an open-label, controlled, multisite, two-arm parallel group clinical trial of 36-month duration to evaluate the continued safety and efficacy of SightGlass Vision Diffusion Optics Technology (DOT) Spectacles in reducing the progression of juvenile myopia.
What is the current status of trial NCT04947735?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 200 participants. The study started on 2021-07-19. Estimated completion is 2026-03-31.
What conditions does trial NCT04947735 study?
This clinical trial studies the following conditions: Myopia, Juvenile Myopia.
What interventions are being tested in trial NCT04947735?
The interventions under investigation include: Novel spectacle lens design (DEVICE), Spectacle lenses (DEVICE).
Who is sponsoring clinical trial NCT04947735?
This trial is sponsored by SightGlass Vision, which has 8 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04947735 being conducted?
This trial has 12 study locations across California, Florida, Kansas, Louisiana, Missouri. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Myopia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04947735's enrollment target sits among peer trials
200 24th of 90 higher than 67 of 90 other Myopia trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Myopia trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Efficacy of Repeated Low-level Red-light Therapy in Myopia Control
RECRUITING · NA
-
Comprehensive Assessment of Multiple Products (CAMP)
RECRUITING · NA
-
Children's Viewing Behavior
RECRUITING · NA
-
Violet Light for the Suppression of Myopia
RECRUITING · NA
-
Measuring Outcomes of LASIK and EVO-ICL in Matched Populations
RECRUITING · NA
-
Wavelength Intervention for Nearsighted Kids
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00107289 · 200 participants · Phase 2
Iodine I 131 Metaiodobenzylguanidine in Treating Patients With Recurrent, Progressive, or Refractory Neuroblastoma or Malignant Pheochromocytoma or Paraganglioma
- NCT00109174 · 200 participants · NA
MRS Measurement of Glutamate and GABA Metabolism in Brain
- NCT00177268 · 200 participants
Blood, Urine, and Tissue Collection for Cutaneous Lymphoma, Eczema, and Atopic Dermatitis Research
- NCT00493688 · 200 participants
A Study to Determine Whether Perioperative Energy Dynamics Correlates With Postoperative Outcomes
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI